Enhancing Incretin Action for the Treatment of Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 175 of the 175 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—To examine the mechanisms of action, therapeutic potential, and challenges inherent in the use of incretin peptides and dipeptidyl peptidase-IV (DPP-IV) inhibitors for the treatment of type 2 diabetes. RESEARCH DESIGN AND METHODS—The scientific literature describing the biological importance of incretin peptides and DPP-IV inhibitors in the control of glucose homeostasis has been reviewed, with an emphasis on mechanisms of action, experimental diabetes, human physiological experiments, and short-term clinical studies in normal and diabetic human subjects. RESULTS—Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) exert important effects on β-cells to stimulate glucose-dependent insulin secretion. Both peptides also regulate β-cell proliferation and cytoprotection. GLP-1, but not GIP, inhibits gastric emptying, glucagon secretion, and food intake. The glucose-lowering actions of GLP-1, but not GIP, are preserved in subjects with type 2 diabetes. However, native GLP-1 is rapidly degraded by DPP-IV after parenteral administration; hence, degradation-resistant, long-acting GLP-1 receptor (GLP-1R) agonists are preferable agents for the chronic treatment of human diabetes. Alternatively, inhibition of DPP-IV–mediated incretin degradation represents a complementary therapeutic approach, as orally available DPP-IV inhibitors have been shown to lower glucose in experimental diabetic models and human subjects with type 2 diabetes. CONCLUSIONS—GLP-1R agonists and DPP-IV inhibitors have shown promising results in clinical trials for the treatment of type 2 diabetes. The need for daily injections of potentially immunogenic GLP-1–derived peptides and the potential for unanticipated side effects with chronic use of DPP-IV inhibitors will require ongoing scrutiny of the risk-benefit ratio for these new therapies as they are evaluated in the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides
Mentlein, R. (1999) · Regulatory Peptides · doi:10.1016/s0167-0115(99)00089-0 · Cited by 1,272
Casadevall, N., Nataf, J., Viron, B., Kolta, A., Kiladjian, J.-J., Martin-Dupont, P., Michaud, P., Papo, T., Ugo, V., Teyssandier, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011931 · Cited by 1,246
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124 · cited 8×
“Both peptides are equipotent and exhibit identical plasma half-lives and biological activities acting through the same receptor (6,7); however, the majority ( 80%) of circulating active GLP-1 appears to be GLP-1(7-36)amide (8).”
BackgroundInfluentialNauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · cited 8×
“Both peptides are equipotent and exhibit identical plasma half-lives and biological activities acting through the same receptor (6,7); however, the majority ( 80%) of circulating active GLP-1 appears to be GLP-1(7-36)amide (8).”
BackgroundInfluentialEng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 9×
“Both peptides are equipotent and exhibit identical plasma half-lives and biological activities acting through the same receptor (6,7); however, the majority ( 80%) of circulating active GLP-1 appears to be GLP-1(7-36)amide (8).”
BackgroundInfluentialTissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919
Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903 · cited 1×
“GLP-1 PRECLINICAL STUDIES AND PHYSIOLOGICAL ACTIONS — Original observations elucidating a role for GLP-1 in the potentiation of glucosedependent insulin secretion (49–51) and insulin gene expression (52) were followed by experiments demonstrating that GLP-1 also inhibits glucagon secretion (53,54) and gastric emptying…”
BackgroundSelf-citationVilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
Mojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 882
Deacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Plasma Insulin Response to Oral and Intravenous Glucose Administration1
ELRICK, H., STIMMLER, L., HLAD, C. J., & ARAI, Y. (1964) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-24-10-1076 · Cited by 857 · cited 2×
“Circulating levels of GIP(1-42) are normal or slightly increased in type 2 diabetic subjects in the basal or postprandial states (22).”
BackgroundNauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · cited 1×
“Similarly, food intake and body weight are not significantly perturbed in GLP-1R / mice in the CD1 genetic background (96,97).”
BackgroundSelf-citationDeacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792 · cited 1×
“The rapid degradation and clearance of native endogenous and exogenously administered GLP-1 (145) have spurred the clinical development of degradation-resistant GLP-1 analogs with longer durations of action in vivo.”
BackgroundElliott, R. M., Morgan, L. M., Tredger, J. A., Deacon, S., Wright, J., & Marks, V. (1993) · Journal of Endocrinology · doi:10.1677/joe.0.1380159 · Cited by 695
Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670
Nauck, M. A., Heimesaat, M. M., Behle, K., Holst, J. J., Nauck, M. S., Ritzel, R., Hüfner, M., & Schmiegel, W. H. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8355 · Cited by 605 · cited 1×
“Nevertheless, appropriate glucagon responses to hypoglycemia do not appear to be blunted in GLP-1– treated subjects (130), and GLP-1 infusion does not impair normal counterregulatory responses to hypoglycemia in healthy human subjects (131).”
BackgroundVerdich, C., Flint, A., Gutzwiller, J.-P., Näslund, E., Beglinger, C., Hellström, P. M., Long, S. J., Morgan, L. M., Holst, J. J., & Astrup, A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.9.7877 · Cited by 600
Herrmann, C., Göke, R., Richter, G., Fehmann, H.-C., Arnold, R., & Göke, B. (2009) · Digestion · doi:10.1159/000201231 · Cited by 597
Holz IV, G. G., Kiihtreiber, W. M., & Habener, J. F. (1993) · Nature · doi:10.1038/361362a0 · Cited by 594
Exon duplication and divergence in the human preproglucagon gene
Bell, G. I., Sanchez-Pescador, R., Laybourn, P. J., & Najarian, R. C. (1983) · Nature · doi:10.1038/304368a0 · Cited by 593
Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209423200 · Cited by 589
Self-citationThe Influence of GLP-1 on Glucose-Stimulated Insulin Secretion
Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes · doi:10.2337/diabetes.52.2.380 · Cited by 582
Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26
Marguet, D., Baggio, L., Kobayashi, T., Bernard, A.-M., Pierres, M., Nielsen, P. F., Ribel, U., Watanabe, T., Drucker, D. J., & Wagtmann, N. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.120069197 · Cited by 538
Self-citationGutzwiller, J.-P., Drewe, J., Göke, B., Schmidt, H., Rohrer, B., Lareida, J., & Beglinger, C. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.276.5.r1541 · Cited by 521
T., V., T., K., S., M., & J., H. (2002) · Diabetologia · doi:10.1007/s00125-002-0878-6 · Cited by 518
Agersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510 · cited 1×
“NN2211 (liraglutide) is a fatty acid– linked DPP-IV–resistant derivative of GLP-1 designed for subcutaneous administration that exhibits a pharmacokinetic profile compatible with once-daily injection (153).”
BackgroundGlucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats
Farilla, L., Hui, H., Bertolotto, C., Kang, E., Bulotta, A., Di Mario, U., & Perfetti, R. (2002) · Endocrinology · doi:10.1210/en.2002-220405 · Cited by 502 · cited 1×
“Reduced islet apoptosis has been observed in GLP-1–treated Zucker diabetic rats (83) and in exendin-4–treated mice after streptozotocin-induced -cell injury (70).”
BackgroundInhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Holst, J. J., & Deacon, C. F. (1998) · Diabetes · doi:10.2337/diabetes.47.11.1663 · Cited by 487
Glucagon-Like Peptides: Regulators of Cell Proliferation, Differentiation, and Apoptosis
Drucker, D. J. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0306 · Cited by 483
Self-citationEnergy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
Näslund, E., Barkeling, B., King, N., Gutniak, M., Blundell, J., Holst, J., Rössner, S., & Hellström, P. (1999) · International Journal of Obesity · doi:10.1038/sj.ijo.0800818 · Cited by 468
Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers
Edwards, C. M. B., Stanley, S. A., Davis, R., Brynes, A. E., Frost, G. S., Seal, L. J., Ghatei, M. A., & Bloom, S. R. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.1.e155 · Cited by 464
Role of the Vagus Nerve in Mediating Proximal Nutrient-Induced Glucagon-Like Peptide-1 Secretion
Rocca, A. S., & Brubaker, P. L. (1999) · Endocrinology · doi:10.1210/en.140.4.1687 · Cited by 464
Miyawaki, K., Yamada, Y., Yano, H., Niwa, H., Ban, N., Ihara, Y., Kubota, A., Fujimoto, S., Kajikawa, M., Kuroe, A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14843 · Cited by 454
Vilsbøll, T., Agersø, H., Krarup, T., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021053 · Cited by 444 · cited 9×
“Both peptides are equipotent and exhibit identical plasma half-lives and biological activities acting through the same receptor (6,7); however, the majority ( 80%) of circulating active GLP-1 appears to be GLP-1(7-36)amide (8).”
BackgroundInfluentialPerfetti, R. (2000) · Endocrinology · doi:10.1210/en.141.12.4600 · Cited by 442
Young, A. A., Gedulin, B. R., Bhavsar, S., Bodkin, N., Jodka, C., Hansen, B., & Denaro, M. (1999) · Diabetes · doi:10.2337/diabetes.48.5.1026 · Cited by 440
Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms
I˙meryüz, N., Yeğen, B. Ç., Bozkurt, A., Coşkun, T., Villanueva-Peñacarrillo, M. L., & Ulusoy, N. B. (1997) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1997.273.4.g920 · Cited by 432
Ahrén, B., Simonsson, E., Larsson, H., Landin-Olsson, M., Torgeirsson, H., Jansson, P.-A., Sandqvist, M., Båvenholm, P., Efendic, S., Eriksson, J. W., et al. (2002) · Diabetes Care · doi:10.2337/diacare.25.5.869 · Cited by 421
Deacon, C. F., Nauck, M. A., Meier, J., Hücking, K., & Holst, J. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.10.6855 · Cited by 401
ØRSKOV, C., HOLST, J. J., & NIELSEN, O. V. (1988) · Endocrinology · doi:10.1210/endo-123-4-2009 · Cited by 396
Flint, A., Raben, A., Ersbøll, A., Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801627 · Cited by 384 · cited 1×
“The acute reduction in food consumption and inhibition of gastric emptying has been detected even with physiological increases in levels of circulating GLP-1 (136).”
BackgroundIntestinal Factors in the Control of Insulin Secretion
McINTYRE, N., HOLDSWORTH, C. D., & TURNER, D. S. (1965) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-25-10-1317 · Cited by 381
CD26: A Multifunctional Integral Membrane and Secreted Protein of Activated Lymphocytes
Gorrell, M. D., Gysbers, V., & McCaughan, G. W. (2001) · Scandinavian Journal of Immunology · doi:10.1046/j.1365-3083.2001.00984.x · Cited by 363
Tourrel, C., Bailbé, D., Meile, M.-J., Kergoat, M., & Portha, B. (2001) · Diabetes · doi:10.2337/diabetes.50.7.1562 · Cited by 362
Fineman, M. S., Bicsak, T. A., Shen, L. Z., Taylor, K., Gaines, E., Varns, A., Kim, D., & Baron, A. D. (2003) · Diabetes Care · doi:10.2337/diacare.26.8.2370 · Cited by 353
Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance
Conarello, S. L., Li, Z., Ronan, J., Roy, R. S., Zhu, L., Jiang, G., Liu, F., Woods, J., Zycband, E., Moller, D. E., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0631828100 · Cited by 347
Edwards, C. M., Todd, J. F., Mahmoudi, M., Wang, Z., Wang, R. M., Ghatei, M. A., & Bloom, S. R. (1999) · Diabetes · doi:10.2337/diabetes.48.1.86 · Cited by 344 · cited 1×
“Comparable studies with exendin(9-39) in humans have demonstrated the essential role of GLP-1 action for glucose control via regulation of glucagon and insulin secretion (89,90).”
BackgroundToft-Nielsen, M. B., Madsbad, S., & Holst, J. J. (1999) · Diabetes Care · doi:10.2337/diacare.22.7.1137 · Cited by 338
Pospisilik, J. A., Martin, J., Doty, T., Ehses, J. A., Pamir, N., Lynn, F. C., Piteau, S., Demuth, H.-U., McIntosh, C. H. S., & Pederson, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.3.741 · Cited by 332
Creutzfeldt, W. O. C., Kleine, N., Willms, B., Ørskov, C., Holst, J. J., & Nauck, M. A. (1996) · Diabetes Care · doi:10.2337/diacare.19.6.580 · Cited by 330
Ørskov, C., Wettergren, A., & Holst, J. J. (1993) · Diabetes · doi:10.2337/diab.42.5.658 · Cited by 325
Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice
Wang, Q., & Brubaker, P. (2002) · Diabetologia · doi:10.1007/s00125-002-0828-3 · Cited by 312
Abraham, E. J. (2002) · Endocrinology · doi:10.1210/en.143.8.3152 · Cited by 310
Elahi, D., McAloon-Dyke, M., Fukagawa, N. K., Meneilly, G. S., Sclater, A. L., Minaker, K. L., Habener, J. F., & Andersen, D. K. (1994) · Regulatory Peptides · doi:10.1016/0167-0115(94)90136-8 · Cited by 309
Hui, H., Nourparvar, A., Zhao, X., & Perfetti, R. (2003) · Endocrinology · doi:10.1210/en.2002-220897 · Cited by 307
Exendin-4 Decelerates Food Intake, Weight Gain, and Fat Deposition in Zucker Rats
Szayna, M. (2000) · Endocrinology · doi:10.1210/en.141.6.1936 · Cited by 303
Meeran, K., O’Shea, D., Edwards, C. M. B., Turton, M. D., Heath, M. M., Gunn, I., Abusnana, S., Rossi, M., Small, C. J., Goldstone, A. P., et al. (1999) · Endocrinology · doi:10.1210/endo.140.1.6421 · Cited by 303 · cited 1×
“Acute intracerebroventricular injection of exendin(9-39) increases food intake in satiated rats (56), whereas repeated daily intracerebroventricular administration of exendin(9-39) increases food intake and weight gain (57).”
BackgroundDeacon, C. F. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.10.3575 · Cited by 301
Kinzig, K. P., D'Alessio, D. A., & Seeley, R. J. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-23-10470.2002 · Cited by 296
Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM
Nauck, M. A., Wollschläger, D., Werner, J., Holst, J. J., Ørskov, C., Creutzfeldt, W., & Willms, B. (1996) · Diabetologia · doi:10.1007/s001250050613 · Cited by 285
Tourrel, C., Bailbe, D., Lacorne, M., Meile, M.-J., Kergoat, M., & Portha, B. (2002) · Diabetes · doi:10.2337/diabetes.51.5.1443 · Cited by 285
D'Alessio, D. A., Kahn, S. E., Leusner, C. R., & Ensinck, J. W. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117225 · Cited by 282
Rolin, B., Larsen, M. O., Gotfredsen, C. F., Deacon, C. F., Carr, R. D., Wilken, M., & Knudsen, L. B. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00030.2002 · Cited by 281
Glucagonlike Peptide I (7–37) Actions on Endocrine Pancreas
Weir, G. C., Mojsov, S., Hendrick, G. K., & Habener, J. F. (1989) · Diabetes · doi:10.2337/diab.38.3.338 · Cited by 275
Rachman, J., Barrow, B. A., Levy, J. C., & Turner, R. C. (1997) · Diabetologia · doi:10.1007/s001250050664 · Cited by 269
Durinx, C., Lambeir, A., Bosmans, E., Falmagne, J., Berghmans, R., Haemers, A., Scharpé, S., & De Meester, I. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01634.x · Cited by 267
GIF biology and fat metabolism
Yip, R. G. C., & Wolfe, M. M. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00314-8 · Cited by 266
Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans
Schirra, J., Sturm, K., Leicht, P., Arnold, R., Göke, B., & Katschinski, M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1349 · Cited by 265
Juhl, C. B., Hollingdal, M., Sturis, J., Jakobsen, G., Agersø, H., Veldhuis, J., Pørksen, N., & Schmitz, O. (2002) · Diabetes · doi:10.2337/diabetes.51.2.424 · Cited by 264
Neonatal Exendin-4 Prevents the Development of Diabetes in the Intrauterine Growth Retarded Rat
Stoffers, D. A., Desai, B. M., DeLeon, D. D., & Simmons, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.3.734 · Cited by 261
Larsen, P. J., Fledelius, C., Knudsen, L. B., & Tang-Christensen, M. (2001) · Diabetes · doi:10.2337/diabetes.50.11.2530 · Cited by 257
Egan, J. M. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.3.1282 · Cited by 256
Knudsen, L. B., & Pridal, L. (1996) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00795-9 · Cited by 248
Trümper, A., Trümper, K., Trusheim, H., Arnold, R., Göke, B., & Hörsch, D. (2001) · Molecular Endocrinology · doi:10.1210/mend.15.9.0688 · Cited by 238
Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes
Drucker, D. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.1.87 · Cited by 237
Self-citationPospisilik, J. A., Stafford, S. G., Demuth, H.-U., Brownsey, R., Parkhouse, W., Finegood, D. T., McIntosh, C. H. S., & Pederson, R. A. (2002) · Diabetes · doi:10.2337/diabetes.51.4.943 · Cited by 232
Meier, J. J., Hücking, K., Holst, J. J., Deacon, C. F., Schmiegel, W. H., & Nauck, M. A. (2001) · Diabetes · doi:10.2337/diabetes.50.11.2497 · Cited by 230
Rask, E., Olsson, T., Söderberg, S., Johnson, O., Seckl, J., Holst, J. J., & Ahrén, B. (2001) · Diabetes Care · doi:10.2337/diacare.24.9.1640 · Cited by 229
Ritzel, R., �rskov, C., Holst, J. J., & Nauck, M. A. (1995) · Diabetologia · doi:10.1007/bf00401846 · Cited by 210
Development and Characterization of a Glucagon-Like Peptide 1-Albumin Conjugate
Kim, J.-G., Baggio, L. L., Bridon, D. P., Castaigne, J.-P., Robitaille, M. F., Jetté, L., Benquet, C., & Drucker, D. J. (2003) · Diabetes · doi:10.2337/diabetes.52.3.751 · Cited by 210
Self-citationBalkan, B., Kwasnik, L., Miserendino, R., Holst, J. J., & Li, X. (1999) · Diabetologia · doi:10.1007/s001250051445 · Cited by 209
Lynn, F. C., Pamir, N., Ng, E. H. C., McIntosh, C. H. S., Kieffer, T. J., & Pederson, R. A. (2001) · Diabetes · doi:10.2337/diabetes.50.5.1004 · Cited by 208
Cardiac Function in Mice Lacking the Glucagon-Like Peptide-1 Receptor
Gros, R., You, X., Baggio, L. L., Kabir, M. G., Sadi, A. M., Mungrue, I. N., Parker, T. G., Huang, Q., Drucker, D. J., & Husain, M. (2003) · Endocrinology · doi:10.1210/en.2003-0007 · Cited by 193
Self-citationImproved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice
Ahrén, B., Holst, J. J., Mårtensson, H., & Balkan, B. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00600-2 · Cited by 193
Trumper, A., Trumper, K., & Horsch, D. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1740233 · Cited by 193
Central infusion of GLP-1, but not leptin, produces conditioned taste aversions in rats
Thiele, T. E., Van Dijk, G., Campfield, L. A., Smith, F. J., Burn, P., Woods, S. C., Bernstein, I. L., & Seeley, R. J. (1997) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1997.272.2.r726 · Cited by 193
Glucagon-like peptide-1 is a physiological incretin in rat.
Wang, Z., Wang, R. M., Owji, A. A., Smith, D. M., Ghatei, M. A., & Bloom, S. R. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117671 · Cited by 190
Greig, N. H., Holloway, H. W., De Ore, K. A., Jani, D., Wang, Y., Zhou, J., Garant, M. J., & Egan, J. M. (1999) · Diabetologia · doi:10.1007/s001250051111 · Cited by 189
Kolligs, F., Fehmann, H.-C., Göke, R., & Göke, B. (1995) · Diabetes · doi:10.2337/diab.44.1.16 · Cited by 185
Schjoldager, B. T. G., Mortensen, P. E., Christiansen, J., �rskov, C., & Holst, J. J. (1989) · Digestive Diseases and Sciences · doi:10.1007/bf01540341 · Cited by 178
Vahl, T. P., Paty, B. W., Fuller, B. D., Prigeon, R. L., & D’Alessio, D. A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021479 · Cited by 173
Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats.
Wang, Y., Perfetti, R., Greig, N. H., Holloway, H. W., DeOre, K. A., Montrose-Rafizadeh, C., Elahi, D., & Egan, J. M. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119482 · Cited by 172
Role of Endogenous Glucagon-Like Peptide-1 in Islet Regeneration After Partial Pancreatectomy
De León, D. D., Deng, S., Madani, R., Ahima, R. S., Drucker, D. J., & Stoffers, D. A. (2003) · Diabetes · doi:10.2337/diabetes.52.2.365 · Cited by 172
Self-citationLarsen, J., Hylleberg, B., Ng, K., & Damsbo, P. (2001) · Diabetes Care · doi:10.2337/diacare.24.8.1416 · Cited by 171
Glucagon-Like Peptide I Reduces Postprandial Glycemic Excursions in IDDM
Dupré, J., Behme, M., Hramiak, I., McFarlane, P. G., Williamson, M., Zabel, P., & Mcdonald, T. (1995) · Diabetes · doi:10.2337/diab.44.6.626 · Cited by 169
Seeley, R. J., Blake, K., Rushing, P. A., Benoit, S., Eng, J., Woods, S. C., & D'Alessio, D. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-04-01616.2000 · Cited by 169
Chen, Y. E., & Drucker, D. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4108 · Cited by 166
Self-citationSudre, B., Broqua, P., White, R. B., Ashworth, D., Evans, D. M., Haigh, R., Junien, J.-L., & Aubert, M. L. (2002) · Diabetes · doi:10.2337/diabetes.51.5.1461 · Cited by 165
Miholic, J., �rskov, C., Holst, J. J., Kotzerke, J., & Meyer, H.-J. (1991) · Digestive Diseases and Sciences · doi:10.1007/bf01296800 · Cited by 163
Anini, Y. (2002) · Endocrinology · doi:10.1210/en.143.6.2420 · Cited by 161
Initiation of Increased Pancreatic Islet Growth in Young Normoglycemic Mice (Umea +/?)
Edvell, A. (1999) · Endocrinology · doi:10.1210/en.140.2.778 · Cited by 154
Krarup, T., Saurbrey, N., Moody, A. J., Kühl, C., & Madsbad, S. (1987) · Metabolism · doi:10.1016/0026-0495(87)90153-3 · Cited by 146
Hui, H., Farilla, L., Merkel, P. A., & Perfetti, R. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460863 · Cited by 144
Gault, V. A., O'Harte, F. P. M., Harriott, P., Mooney, M., Green, B., & Flatt, P. R. (2003) · Diabetologia · doi:10.1007/s00125-002-1028-x · Cited by 139
Gutniak, M. K., Linde, B., Holst, J. J., & Efendić, S. (1994) · Diabetes Care · doi:10.2337/diacare.17.9.1039 · Cited by 139
Pospisilik, J. A., Stafford, S. G., Demuth, H.-U., McIntosh, C. H. S., & Pederson, R. A. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2677 · Cited by 138
Goldstone, A. P., Mercer, J. G., Gunn, I., Moar, K. M., Edwards, C. M. B., Rossi, M., Howard, J. K., Rasheed, S., Turton, M. D., Small, C., et al. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01103-4 · Cited by 131
Hinke, S. A., Gelling, R. W., Pederson, R. A., Manhart, S., Nian, C., Demuth, H.-U., & McIntosh, C. H. S. (2002) · Diabetes · doi:10.2337/diabetes.51.3.652 · Cited by 131
D'Alessio, D. A., Vogel, R., Prigeon, R., Laschansky, E., Koerker, D., Eng, J., & Ensinck, J. W. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118380 · Cited by 122
D'Alessio, D. A., Prigeon, R. L., & Ensinck, J. W. (1995) · Diabetes · doi:10.2337/diab.44.12.1433 · Cited by 122
A functional role for central glucagon-like peptide-1 receptors in lithium chloride-induced anorexia
Rinaman, L. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.277.5.r1537 · Cited by 121
Donahey, J. C. K., van Dijk, G., Woods, S. C., & Seeley, R. J. (1998) · Brain Research · doi:10.1016/s0006-8993(97)01057-3 · Cited by 120
Vella, A. V., Shah, P., Basu, R., Basu, A., Holst, J. J., & Rizza, R. A. (2000) · Diabetes · doi:10.2337/diabetes.49.4.611 · Cited by 119
Sequence of an intestinal cDNA encoding human gastric inhibitory polypeptide precursor.
Takeda, J., Seino, Y., Tanaka, K., Fukumoto, H., Kayano, T., Takahashi, H., Mitani, T., Kurono, M., Suzuki, T., & Tobe, T. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.20.7005 · Cited by 115
Scrocchi, L. A., Marshall, B. A., Cook, S. M., Brubaker, P. L., & Drucker, D. J. (1998) · Diabetes · doi:10.2337/diabetes.47.4.632 · Cited by 114
Self-citationNauck, M. A., Sauerwald, A., Ritzel, R. A., Holst, J. J., & Schmiegel, W. (1998) · Diabetes Care · doi:10.2337/diacare.21.11.1925 · Cited by 113
Is glucagon-like peptide 1 an incretin hormone?
Nauck, M. A. (1999) · Diabetologia · doi:10.1007/s001250051165 · Cited by 112
Qualmann, C., Nauck, M. A., Holst, J. J., �rskov, C., & Creutzfeldt, W. (1995) · Acta Diabetologica · doi:10.1007/bf00581038 · Cited by 111
Deacon, C. F., Plamboeck, A., Møller, S., & Holst, J. J. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00452.2001 · Cited by 110
Glucagon-like peptide-1 (7–36) amide: a central regulator of satiety and interoceptive stress
van Dijk, G., & Thiele, T. E. (1999) · Neuropeptides · doi:10.1054/npep.1999.0053 · Cited by 107
Toft-Nielsen, M.-B., Madsbad, S., & Holst, J. J. (1996) · Diabetes · doi:10.2337/diab.45.5.552 · Cited by 105
Movassat, J., Beattie, G. M., Lopez, A. D., & Hayek, A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020137 · Cited by 104
Gault, V., Parker, J., Harriott, P., Flatt, P., & O'Harte, F. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1750525 · Cited by 103
Yan, S., Marguet, D., Dobers, J., Reutter, W., & Fan, H. (2003) · European Journal of Immunology · doi:10.1002/eji.200323469 · Cited by 97
Lewis, J. T., Dayanandan, B., Habener, J. F., & Kieffer, T. J. (2000) · Endocrinology · doi:10.1210/endo.141.10.7750 · Cited by 96
Stimulation of Release of Insulin by an Extract of Intestinal Mucosa
Duprè, J., & Beck, J. C. (1966) · Diabetes · doi:10.2337/diab.15.8.555 · Cited by 96
Nagakura, T., Yasuda, N., Yamazaki, K., Ikuta, H., Yoshikawa, S., Asano, O., & Tanaka, I. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4999 · Cited by 95
Scrocchi, L. A., & Drucker, D. J. (1998) · Endocrinology · doi:10.1210/endo.139.7.6092 · Cited by 95
Self-citationGlucagon-like peptide 1 receptor signaling influences topography of islet cells in mice
Ling, Z., Wu, D., Zambre, Y., Flamez, D., Drucker, D. J., PIPELEERS, D. G., & Schuit, F. C. (2001) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s004280000374 · Cited by 95
Self-citationEffect of GIP and GLP-1 antagonists on insulin release in the rat
Tseng, C.-C., Zhang, X.-Y., & Wolfe, M. M. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.276.6.e1049 · Cited by 95
Glucagon-like peptide-1 (7–36)-NH2: a physiological inhibitor of gastric acid secretion in man
O'Halloran, D. J., Nikou, G. C., Kreymann, B., Ghatei, M. A., & Bloom, S. R. (1990) · Journal of Endocrinology · doi:10.1677/joe.0.1260169 · Cited by 91
Trumper, A. (2001) · Molecular Endocrinology · doi:10.1210/me.15.9.1559 · Cited by 90
Glucagon‐like peptide‐1 (GLP‐1): a trial of treatment in non‐insulin‐dependent diabetes mellitus
TODD, J. F., WILDING, J. P. H., EDWARDS, C. M. B., KHAN, F. A., GHATEI, M. A., & BLOOM, S. R. (1997) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.1997.1490691.x · Cited by 87
Ribel, U., Larsen, M. O., Rolin, B., Carr, R. D., Wilken, M., Sturis, J., Westergaard, L., Deacon, C. F., & Knudsen, L. B. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02189-1 · Cited by 84
Ryan, A. S., Egan, J. M., Habener, J. F., & Elahi, D. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.7.4988 · Cited by 84
Lugari, R., Dei Cas, A., Ugolotti, D., Finardi, L., Barilli, A., Ognibene, C., Luciani, A., Zandomeneghi, R., & Gnudi, A. (2002) · Hormone and Metabolic Research · doi:10.1055/s-2002-23199 · Cited by 84
Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes
Egan, J. M., Meneilly, G. S., & Elahi, D. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00315.2002 · Cited by 83
Jones, I. R., Owens, D. R., Moody, A. J., Luzio, S. D., Morris, T., & Hayes, T. M. (1987) · Diabetologia · doi:10.1007/bf00296993 · Cited by 82
Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes.
Nielsen, L. L., & Baron, A. (2003) · PubMed · Cited by 82
Functional Maturation of Fetal Porcine β-Cells by Glucagon-Like Peptide 1 and Cholecystokinin
Hardikar, A. A., Wang, X. Y., Williams, L. J., Kwok, J. C., Wong, R., Yao, M., & Tuch, B. E. (2002) · Endocrinology · doi:10.1210/en.2001-211344 · Cited by 81
Baggio, L. (2000) · Endocrinology · doi:10.1210/en.141.10.3703 · Cited by 79
O'Harte, F. P. M., Gault, V. A., Parker, J. C., Harriott, P., Mooney, M. H., Bailey, C. J., & Flatt, P. R. (2002) · Diabetologia · doi:10.1007/s00125-002-0894-6 · Cited by 73
Gelling, R. W., Coy, D. H., Pederson, R. A., Wheeler, M. B., Hinke, S. A., Kwan, T., & McIntosh, C. H. S. (1997) · Regulatory Peptides · doi:10.1016/s0167-0115(97)00009-8 · Cited by 71
Gutniak, M. K., Juntti-Berggren, L., Hellström, P. M., Guenifi, A., Holst, J. J., & Efendic, S. (1996) · Diabetes Care · doi:10.2337/diacare.19.8.857 · Cited by 70
Ryan, A. S. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.7.2399 · Cited by 65
Glucagon-like peptide-1 (7–36 amide): a potent glucagonostatic and insulinotropic hormone
Matsuyama, T., Komatsu, R., Namba, M., Watanabe, N., Itoh, H., & Tarui, S. (1988) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(88)80063-9 · Cited by 64
Juntti-Berggren, L., Pigon, J., Karpe, F., Hamsten, A., Gutniak, M., Vignati, L., & Efendic, S. (1996) · Diabetes Care · doi:10.2337/diacare.19.11.1200 · Cited by 63
Ritzel, R., Schulte, M., Pørksen, N., Nauck, M. S., Holst, J. J., Juhl, C., März, W., Schmitz, O., Schmiegel, W. H., & Nauck, M. A. (2001) · Diabetes · doi:10.2337/diabetes.50.4.776 · Cited by 62
Scrocchi, L. A., Hill, M. E., Saleh, J., Perkins, B., & Drucker, D. J. (2000) · Diabetes · doi:10.2337/diabetes.49.9.1552 · Cited by 61
Self-citationAdditive Glucose-Lowering Effects of Glucagon-Like Peptide-1 and Metformin in Type 2 Diabetes
Zander, M., Taskiran, M., Toft-Nielsen, M.-B., Madsbad, S., & Holst, J. J. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.720 · Cited by 61
EDWARDS, C. M. B., TODD, J. F., GHATEI, M. A., & BLOOM, S. R. (1998) · Clinical Science · doi:10.1042/cs0950719 · Cited by 57
Tseng, C. C., Boylan, M. O., Jarboe, L. A., Usdin, T. B., & Wolfe, M. M. (1996) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1996.270.4.e661 · Cited by 56
Byrne, M. M., Gliem, K., Wank, U., Arnold, R., Katschinski, M., Polonsky, K. S., & Goke, B. (1998) · Diabetes · doi:10.2337/diab.47.8.1259 · Cited by 55
Davis, H. R., Mullins, D. E., Pines, J. M., Hoos, L. M., France, C. F., Compton, D. S., Graziano, M. P., Sybertz, E. J., Strader, C. D., & Van Heek, M. (1998) · Obesity Research · doi:10.1002/j.1550-8528.1998.tb00329.x · Cited by 55
O'Harte, F. P. M., Mooney, M., Kelly, C. M., & Flatt, P. R. (2000) · Journal of Endocrinology · doi:10.1677/joe.0.1650639 · Cited by 50
The Effect of Glyburide on β-Cell Sensitivity to Glucose-Dependent Insulinotropic Polypeptide
Meneilly, G. S., Bryer‐Ash, M., & Elahi, D. (1993) · Diabetes Care · doi:10.2337/diacare.16.1.110 · Cited by 41
Dachicourt, N., Serradas, P., Bailbé, D., Kergoat, M., Doaré, L., & Portha, B. (1997) · Journal of Endocrinology · doi:10.1677/joe.0.1550369 · Cited by 40
Hargrove, D. M., Nardone, N. A., Persson, L. M., Parker, J. C., & Stevenson, R. W. (1995) · Metabolism · doi:10.1016/0026-0495(95)90021-7 · Cited by 36
Byrne, M. M., Gliem, K., Wank, U., Arnold, R., Katschinski, M., Polonsky, K. S., & Göke, B. (1998) · Diabetes · doi:10.2337/diabetes.47.8.1259 · Cited by 32
Leptin Sensitivity in Nonobese Glucagon-Like Peptide I Receptor −/− Mice
Scrocchi, L. A., Brown, T. J., & Drucker, D. J. (1997) · Diabetes · doi:10.2337/diab.46.12.2029 · Cited by 22
Self-citationJia, X., Elliott, R. M., Kwok, Y. N., Pederson, R. A., & McIntosh, C. H. S. (1995) · Diabetes · doi:10.2337/diab.44.5.495 · Cited by 18
Jones, I. R., Owens, D. S., Luzio, S. D., & Tm, H. (1989) · Hormone and Metabolic Research · doi:10.1055/s-2007-1009141 · Cited by 15
Shen, H.-Q., Roth, M., & Peterson, R. G. (1998) · Metabolism · doi:10.1016/s0026-0495(98)90275-x · Cited by 11
Jones, I. R., Owens, D. R., Vora, J. P., Luzio, S. D., & Hayes, T. M. (1989) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(89)90014-4 · Cited by 7
Cited by
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Heine, R. J., Van Gaal, L. F., Johns, D., Mihm, M. J., Widel, M. H., Brodows, R. G., & for the GWAA Study Group* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-8-200510180-00006 · Cited by 795
β-Cell Failure in Diabetes and Preservation by Clinical Treatment
Wajchenberg, B. L. (2007) · Endocrine Reviews · doi:10.1210/10.1210/er.2006-0038 · Cited by 714
Augeri, D. J., Robl, J. A., Betebenner, D. A., Magnin, D. R., Khanna, A., Robertson, J. G., Wang, A., Simpkins, L. M., Taunk, P., Huang, Q., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050261p · Cited by 624
Glucose Metabolism and Regulation: Beyond Insulin and Glucagon
Aronoff, S. L., Berkowitz, K., Shreiner, B., & Want, L. (2004) · Diabetes Spectrum · doi:10.2337/diaspect.17.3.183 · Cited by 569
Metadata
- Authors
- Drucker, D. J.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2003-10-01
- Volume
- 26
- Issue
- 10
- Pages
- 2929-2940
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2108771199
- Cited by
- 579
- References
- 175
- FWCI
- 20.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.